Psychedelics
DENVER, April 07, 2021 — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, has announced its four lead novel drug candidates as the Company prepares for its Pre-Investigational New Drug (IND) meetings with […]
Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology
Agreement to explore the use of Silo Pharma’s Novel Peptide Englewood Cliffs, NJ, April 07, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has finalized an agreement to sublicense the technology covered by its recently announced […]
NeonMind Developing Music Playlist For Psychedelic Therapy Sessions
Vancouver, B.C. – April 6, 2021: NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) (OTC:NMDBF) (“NeonMind”), is pleased to announce the commencement of a three phase university study dedicated to creating an ideal music playlist to accompany therapeutic psychedelic sessions. Previous research has established that music for a therapeutic psychedelic session can significantly impact the experience. […]
Seelos Therapeutics Announces a Strategic Device Partnership with AptarGroup, Inc.
NEW YORK, April 6, 2021 /PRNewswire/ — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced today the signing of an agreement between Seelos and AptarGroup, Inc. (NYSE: ATR) for the co-exclusive use and supply of Aptar Pharma’s Bidose (BDS) Liquid System device […]
Core One Labs Vocan Expands Product Commercialization Team
VANCOUVER, BC / ACCESSWIRE / April 6, 2021 / Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt:LD62) (WKN: A2P8K3) (“Core One“) is pleased to announce its wholly-owned subsidiary Vocan Biotechnologies Inc. (“Vocan“) has expanded its product commercialization team, adding Dr. Elizabeth Matthews as Head of Scientific and Regulatory Affairs. Dr. Matthews will oversee research and development, as well […]
Optimi Health Aims to Expand its Shareholder Base
VANCOUVER, BC (GLOBE NEWSWIRE – April 6, 2021) — Optimi Health Corp. (CSE: OPTI) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce the addition of their overseas listing. The commencement of equity trading in Optimi securities is on the premier […]
Entheon Biomedical Corp. Launches HaluGen’s Psychedelics Genetic Test
HaluGen’s DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapy Vancouver, British Columbia–(Newsfile Corp. – April 6, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces the launch of the industry’s first Psychedelics […]
MindMed Announces the Publication of New Data on Personalized MDMA Dosing
BASEL, Switzerland, April 5, 2021 /CNW/ — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading clinical-stage psychedelic medicine biotech company, announced the publication of the first study on MDMA dosing optimization using personalized medicine. The study took place at the University Hospital Basel Liechti Lab, in Basel, Switzerland. This study provides the first scientific […]
Dr. Spigarelli’s extensive clinical and research development expertise will be integral in leading PsyBio’s development and clinical goals OXFORD, Ohio and COCONUT CREEK, Fla., April 5, 2021 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (“PsyBio“), a biotechnology company pioneering the next generation of targeted psychoactive medications, today announced the appointment of Michael Spigarelli, M.D., Ph.D., […]
Tryp Therapeutics Appoints Greg McKee as Chief Executive Officer
San Diego, California–(Newsfile Corp. – April 1, 2021) – Tryp Therapeutics Inc. (CSE: TRYP) (“Tryp” or the “Company“), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, is pleased to announce that it has appointed Greg McKee as its Chief Executive Officer. Mr. McKee will also continue in his responsibilities […]
Vancouver, B.C. – March 30, 2021: NeonMind Biosciences Inc. (CSE: NEON) (FFE: 6UF) (“NeonMind”), a psychedelic drug development company, is pleased to announce that Robert Tessarolo, President & Chief Executive Officer, will be speaking at the Psychedelic, Therapeutics, & Drug Development Conference that will be held virtually from May 4-6. He will be speaking on the use […]
After recently launching its Advanced Analytical Testing services, CBDV successfully receives orders through their new online payment platform VANCOUVER, BC, March 31, 2021 /PRNewswire/ – Delic Holdings Inc. (the “Company”), (“DELIC”) (CSE: DELC) (OTCQB: DELCF), a psychedelic focused wellness company, is pleased to announce that its acquisition target, Complex Biotech Discovery Ventures Ltd. (“CBDV”), a licensed cannabis and […]
Toronto, Ontario–(Newsfile Corp. – March 30, 2021) – Mindset Pharma Inc. (CSE: MSET) (OTCQB: MSSTF) (FSE: 9DF) (“Mindset” or the “Company“), a drug discovery and development company focused on developing next generation psilocybin and N,N-Dimethyltryptamine (DMT) inspired medicines and related technologies, is pleased to announce that it has expanded its scientific leadership team with the appointment of Dr. Malik […]
BetterLife Added to the Horizons Psychedelic Stock Index ETF
BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU ) is pleased to announce that it has been added to the Horizons Psychedelic Stock Index ETF ( PSYK : NEO), the world’s first ETF offering direct exposure to North American publicly listed securities that have significant business activities […]
TORONTO, March 29, 2021 (GLOBE NEWSWIRE) — Psirenity, a wholly owned subsidiary of New Leaf Canada Inc., today announced it has received approval to conduct the first clinical trial protocol with psilocybin in Jamaica. Psirenity is emerging as a global leader in science-backed brain health and wellness. Its focus is on providing holistic treatments that help […]
Mind Medicine (MindMed) Inc. (“MindMed”) (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, has announced the addition of Dr. Robert C. Malenka, an accomplished neuroscientist and psychiatry professor from Stanford University, to Chair the Company’s Scientific Advisory Board. Dr. Malenka is an elected member of the National Academy of Sciences and […]
Core One Labs Appoints Dr. Stephen Peach as Head of Patient Research
Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(FRA:LD62)(WKN:A2P8K3) is pleased to announce that its wholly owned subsidiary Rejuva Mental Health Clinic (the “Clinic”) has retained Dr. Stephen Peach as Lead Physician. Dr. Peach will be responsible for developing comprehensive patient intake and assessment protocols, with the goal of identifying individuals with a history of mental health disorders […]
Von der Schildkröte zum Hasen: Wie KI die Arzneimittelentwicklung beschleunigen will
Alexander Flemmings zufällige Entdeckung von Penicillin steht in krassem Gegensatz zu den typischen Prozessen und Zeitplänen, die mit der Entdeckung von Arzneimitteln verbunden sind. Im Gegenteil, die meisten Medikamente werden nicht versehentlich entdeckt, sondern über lange Zeiträume von 5 bis 15 Jahren entwickelt, was viele Millionen Dollar kostet. Grundsätzlich kann der Entwicklungsprozess in zwei Phasen […]
Creso Pharma Receives Commitments Totaling A$18m
Creso Pharma Limited(ASX:CPH, FRA:1X8) (‘Creso Pharma’) is pleased to advise that it has secured firm commitments from institutional, professional and sophisticated investors to raise up to A$18million (before costs) through the issue of approximately 94.7 million new fully paid ordinary shares (“shares”) at an issue price of $0.19 per share(“Placement”). The Placement was heavily oversubscribed […]
Horizons ETFs Completes Rebalance of World’s First Psychedelics ETF
Horizons ETFs Management (Canada) Inc. (“Horizons ETFs“) has completed its first quarterly rebalance of the holdings of the Horizons Psychedelic Stock Index ETF (PSYK: NEO). PSYK is the world’s first ETF offering direct exposure to North American publicly listed securities that have significant business activities in, or significant exposure to, the psychedelics industry. This quarter, […]
From Tortoise to Hare, How AI Aims to Speed up Drug Development
Alexander Flemming’s accidental discovery of penicillin exists in stark contrast to the typical processes and timelines associated with drug discovery. Most drugs, on the contrary, are not accidentally discovered and are developed over long timelines ranging from 5 to 15 years, costing many millions of dollars. Broadly speaking, the development process can be divided into […]
Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP)(“Havn Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, has entered into a letter of intent (LOI) with nutraceutical company Hypha Wellness Jamaica Psilocybin (HWJP) towards jointly researching and, subject to compliance with all applicable laws and regulations, producing standardized powdered […]
PharmaTher Advancing Research for Novel Microneedle Delivery of Ketamine
Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), today announced that its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), a psychedelics biotech company, has entered into a sponsored research agreement with The Queen’s University of Belfast (“QUB”) for the development of a patented hydrogel-forming microneedle (“MN”) patch to deliver ketamine and the PharmaTher’s proprietary ketamine formulation, KETABET™”. This […]
Psygen Industries Ltd. (“Psygen“) and Larose Ventures Ltd. (“Larose Ventures“) are pleased to announce they have entered into a binding letter agreement (the “Letter Agreement“) dated March 23, 2021, to complete a business combination by way of a transaction that will constitute a reverse takeover of a wholly-owned subsidiary of the Company, being 1290442 B.C. […]
PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin
PsyBio Therapeutics Corp. (TSXV: PSYB) (“PsyBio“), a leader in the field of psychedelic research and drug development, has initiated process development of its proprietary biosynthetic formulation of norbaeocystin in collaboration with the Advanced Biofuels and Bioproducts Process Development Unit, a scale-up facility managed by Lawrence Berkeley National Laboratory, a U.S. Department of Energy national laboratory. […]
Ehave, Inc. (OTC Pink: EHVVF), a provider of digital therapeutics for the psychedelic and mental health sectors, and Silo Wellness Inc. (CSE: SILO) (“Silo Wellness”), a wellness company in the psychedelics and functional mushroom marketplaces, today announced plans to collaborate on a clinical study in coordination with select volunteer participants of Silo Wellness’ Jamaican psilocybin-facilitated […]
Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF)(“Mindset” or the “Company“), a biotechnology company focused on developing next generation psychedelic medicines and related technologies, is pleased to announce that it has entered a co-development agreement with InterVivo Solutions Inc. (“InterVivo” or “IVS“), to co-develop a new translational testing platform that Mindset and InterVivo expect […]
COMPASS Pathways Granted Two US Patents
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it has been granted two new patents by the US Patent and Trademark Office (USPTO). These patents cover oral formulations of COMPASS’s synthetic psilocybin in the treatment of major depressive […]
Mydecine Innovations Group Announces Migration to NEO Exchange
DENVER, March 23, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced that effective as of market open today, March 23, 2021, its common shares […]
MagicMed and Proactive Present Magic Moments Videocast on AI in Psychedelics
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
In addition to his role as Founder and CEO at MAZAKALI, Sumit is a consultant to The Arcview Group and the Managing Partner of Emerald Ventures. A frequent speaker at investment seminars, Sumit acts as a mentor to Arcview and Canopy companies and serves on the Canopy Investment committee as well as the NCIA Finance […]
Tom Zuber is Zuber Lawler & Del Duca’s Managing Partner. He has a degree with highest honors in biomedical engineering and has advised some of the most iconic companies in the world on their patent and trademark portfolios. He is at the cutting edge of cannabis patent and trademark law. He holds degrees from Harvard University and Columbia Law […]
PotBotics is a leading data aggregation and technology company focused on the global medical cannabis market.
Indiva aims to become a house of global marijuana brands, recognized for high quality cannabis products.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
